Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

New England Journal of Medicine

Volumn 377, Issue 20, 2017, Pages 1919-1929

  Antonia, S J ^a   Villegas, A ^b   Daniel, D ^d,e   Vicente, D ^f   Murakami, S ⁱ   Hui, R ^m   Yokoi, T ^j   Chiappori, A ^a   Lee, K H ^o   De Wit, M ^r   Cho, B C ^p   Bourhaba, M ^s   Quantin, X ^t   Tokito, T ^k   Mekhail, T ^c   Planchard, D ^u   Kim, Y C ^q   Karapetis, C S ⁿ   Hiret, S ^v   Ostoros, G ^w   Kubota, K ^l   Gray, J E ^a   Paz Ares, L ^g   De Castro Carpeno J ^h   Wadsworth, C ^z   Melillo, G ^x   Jiang, H ^x   Huang, Y ^x   Dennis, P A ^x   Ozguroglu M ^y   more..

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Cancer Specialists of North Florida   (United States)

^c FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^d Tennessee Oncology   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ KANAGAWA CANCER CENTER   (Japan)

^j KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^k KURUME UNIVERSITY HOSPITAL   (Japan)

^l NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^m UNIVERSITY OF SYDNEY   (Australia)

ⁿ FLINDERS MEDICAL CENTRE   (Australia)

^o Chungbuk National University Hospital   (South Korea)

^p Yonsei University College of Medicine   (South Korea)

^q Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^r VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^s UNIVERSITY OF LIÈGE   (Belgium)

^t MONTPELLIER UNIVERSITY HOSPITAL   (France)

^u INSTITUT GUSTAVE ROUSSY   (France)

^v Site Hospitalier Nord   (France)

^w NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^x ASTRAZENECA   (United Kingdom)

^y ISTANBUL UNIVERSITY   (Turkey)

^z NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DURVALUMAB; ETOPOSIDE; GLUCOCORTICOID; PACLITAXEL; PEMETREXED; PLACEBO; VINBLASTINE; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ANEMIA; AORTIC DISSECTION; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BACTERIAL PNEUMONIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CHEMORADIOTHERAPY; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMPHYSEMA; EOSINOPHILIC COLITIS; FATIGUE; FEMALE; FEVER; HAZARD RATIO; HEADACHE; HEART ARREST; HEART FAILURE; HEART INFARCTION; HEART RIGHT VENTRICLE FAILURE; HEMOPTYSIS; HUMAN; HYPOTHYROIDISM; IMMUNOPATHOLOGY; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; INTESTINE OBSTRUCTION; LUNG FIBROSIS; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYOCARDITIS; NAUSEA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION DOSE; RADIATION PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIA; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VERY ELDERLY; WEST NILE FEVER; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SECONDARY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING;

EID: 85032655147     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1709937     Document Type: Article

References (24)

1. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90.
2. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017;8:1-20.
3. Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KC-SG-LU05-04. J Clin Oncol 2015;33:2660-6.
4. Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017;15: 504-35.
5. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2013;24:Suppl 6:vi89-vi98.
6. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-60.
7. Wozniak AJ, Moon J, Thomas CR Jr, et al. A pilot trial of cisplatin/etoposide/ radiotherapy followed by consolidation docetaxel and the combination of bevaciz-umab (NSC-704865) in patients with inoperable locally advanced stage III non-small-cell lung cancer: SWOG S0533. Clin Lung Cancer 2015;16:340-7.
8. Hoang T, Dahlberg SE, Schiller JH, et al. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol 2012;30:616-22.
9. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26: 2450-6.
10. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187-99.
11. Vokes EE, Herndon JE II, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-704.
12. Tsujino K, Kurata T, Yamamoto S, et al. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature. J Thorac Oncol 2013;8: 1181-9.
13. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68.
14. Mitchell P, Thatcher N, Socinski MA, et al. Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. Ann Oncol 2015; 26:1134-42.
15. Stewart R, Morrow M, Hammond SA, et al. Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 2015;3:1052-62.
16. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
17. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82.
18. Antonia SJ, Brahmer JR, Khleif S, et al. Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC). Presented at the 41st European Society for Medical Oncology Annual Meeting, Copenhagen, October 7–11, 2016. (Poster.)
19. AstraZeneca Imfinzi (durvalumab): highlights of prescribing information. Silver Spring, MD: Food and Drug Administration, April 2017 (https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761069s000lbl.pdf).
20. Zhang P, Su DM, Liang M, Fu J. Chemo-preventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol 2008;45:1470-6.
21. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment syner-gistically promote antitumor immunity in mice. J Clin Invest 2014;124:687-95.
22. Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014;74:5458-68.
23. Goldstraw P, ed. Staging manual in thoracic oncology. 7th ed. Aurora, CO: International Association for the Study of Lung Cancer, 2010.
24. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003;21:2004-10.